List of Excipients in Branded Drug CYSTOGRAFIN DILUTE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
BRACCO DIAGNOSTICS INC	CYSTOGRAFIN DILUTE	diatrizoate meglumine	0270-1410	EDETATE DISODIUM

Cystografin Dilute Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Cystografin Dilute is an older, sterile, water-soluble radiopaque drug product containing diatrizoate meglumine at approximately 18.2% w/v. Its commercial value is tied to formulation simplicity, sterile manufacturing reliability, catheter compatibility, and supply continuity rather than new-molecule patent protection. The strongest opportunities are authorized-generic supply, hospital-contract manufacturing, improved single-use packaging, pediatric urology presentations, and lower-burden sterile products that preserve the labeled clinical performance.

What is Cystografin Dilute and how is it used?

Cystografin Dilute is an intravesical contrast medium used primarily for contrast imaging of the urinary bladder and lower urinary tract. Its active pharmaceutical ingredient is diatrizoate meglumine, an ionic, water-soluble tri-iodinated contrast agent. The dilute concentration is intended for urinary tract imaging where a lower iodine concentration than conventional angiographic or intravenous products is appropriate.

Attribute	Cystografin Dilute
Active ingredient	Diatrizoate meglumine
Strength	Approximately 18.2% w/v
Primary route	Intravesical administration
Main use	Cystography and related lower urinary tract imaging
Dosage form	Sterile aqueous solution
Drug class	Ionic, water-soluble iodinated contrast medium
Primary commercial buyers	Hospitals, radiology departments, urology departments and distributors
Key formulation constraint	Sterility, osmolality, iodine concentration and catheter compatibility
Regulatory category	Prescription drug product regulated by FDA

The product is administered directly into the bladder rather than injected intravenously. That route changes the excipient strategy. The formulation must support sterile urinary tract administration, low particulate burden, physical stability and predictable dilution without creating unnecessary exposure to preservatives or reactive excipients.

The FDA labeling identifies diatrizoate meglumine as the active ingredient and lists a limited excipient system, including water for injection and a chelating or stabilizing component such as edetate disodium, depending on the presentation and current labeling version. Product-specific composition must be controlled against the current approved package insert and Chemistry, Manufacturing, and Controls documentation (FDA, Cystografin Dilute Prescribing Information).

What excipients are used in Cystografin Dilute?

Cystografin Dilute uses a minimal excipient platform. The commercial formulation is not designed as a complex sustained-release or solubilized product. The core excipient functions are solvent, metal-ion control and pH or stability management.

Excipient function	Likely formulation role	Commercial relevance
Water for injection	Vehicle	Provides the sterile aqueous medium
Chelating agent, such as edetate disodium	Controls trace metals that can promote degradation or discoloration	Supports solution stability and manufacturing robustness
pH adjustment	Maintains product compatibility and stability	May be controlled through the active salt system or limited adjustment
Container closure system	Protects sterility and chemical quality	Affects extractables, leachables, adsorption and shelf life

The formulation strategy should remain deliberately narrow. Additional excipients could create new risks without improving clinical performance. Potential problems include:

• Higher osmolality.
• Increased extractables or leachables.
• New compatibility issues with urinary catheters and collection systems.
• More complex regulatory comparability.
• Additional toxicological qualification.
• Greater risk of visible or subvisible particles.
• Reduced flexibility in aseptic filling.

For a legacy intravesical contrast product, excipient reduction is usually more commercially valuable than excipient innovation.

Which excipients offer the greatest formulation opportunity?

The primary opportunity is not to add a novel excipient. It is to optimize the existing excipient architecture while maintaining the same active concentration, iodine delivery and clinical use.

Chelator optimization

A chelating agent can reduce the effect of trace metals introduced through raw materials, water systems, process equipment or packaging. The commercial objective is to use the lowest effective level that maintains stability. Excess chelator can complicate comparability and may create unnecessary regulatory questions.

Development work should evaluate:

• Diatrizoate degradation over the proposed shelf life.
• Color change and visible particle formation.
• Trace-metal sensitivity.
• Compatibility with stainless-steel equipment.
• Interaction with elastomeric closures.
• Stability after partial withdrawal from multidose-use scenarios, if applicable.
• Performance after exposure to temperature excursions.

A reduced-chelator formulation may be attractive if the manufacturer can demonstrate equivalent stability through tighter raw-material controls and improved container closure protection. The value proposition would be lower excipient burden, not a new clinical claim.

pH control

The active meglumine salt contributes substantially to the solution environment. A formulation developer should avoid aggressive pH adjustment unless the current product profile requires it. Strong acid or base additions can affect:

• Chemical stability.
• Container closure compatibility.
• Patient tolerability.
• Osmolality.
• Manufacturing reproducibility.

The most defensible strategy is to establish a narrow pH operating range using the active salt system and validated process controls. A new buffer system would require a clear benefit because it could change osmolality and introduce additional materials into an established product.

Preservative avoidance

A preservative-free, single-dose presentation is commercially preferable for an intravesical product. Preservatives can create compatibility and tolerability concerns, while single-dose packaging removes the need for repeated access to the container.

A manufacturer should avoid adding benzyl alcohol, parabens or other antimicrobial preservatives unless a multidose product is commercially essential and the regulatory pathway specifically supports it. The better opportunity is usually improved single-use packaging, not preservation chemistry.

Surfactants and solubilizers

Surfactants are generally unnecessary because diatrizoate meglumine is already water soluble at the marketed concentration. Surfactants could add risks involving foam, adsorption, container interaction and urinary tract tolerability. They do not offer a strong commercial benefit for the dilute cystography use case.

What formulation patents protect Cystografin Dilute?

The main patent opportunity for Cystografin Dilute is limited because diatrizoate meglumine and conventional aqueous contrast formulations are mature technologies. The likely commercial barriers are regulatory approval, sterile manufacturing capability, supplier qualification and hospital purchasing contracts rather than a strong composition-of-matter patent estate.

Potential protection area	Expected strategic value
Diatrizoate meglumine composition of matter	Low for a legacy active ingredient
Basic aqueous formulation	Low unless a narrow stability or compatibility claim remains enforceable
Chelator concentration	Moderate only if supported by unexpected stability or compatibility results
Container closure system	Moderate where the claim covers a specific low-extractables configuration
Ready-to-use sterile presentation	Moderate through formulation, packaging or device claims
Catheter or delivery system	Moderate to high if a proprietary device is commercialized
Pediatric imaging kit	Moderate through combination-product or workflow claims
Manufacturing process	Moderate where the process solves sterility, particulate or stability problems
Method of use	Usually limited for an established cystography indication
New diagnostic workflow	Higher if combined with a proprietary imaging or catheter system

A serious freedom-to-operate assessment should search U.S. and foreign patent records for:

• "Cystografin."
• "Diatrizoate meglumine."
• "Diatrizoic acid."
• "Urinary bladder contrast."
• "Intravesical contrast."
• "Cystography formulation."
• "Iodinated contrast catheter."
• "Radiopaque urological device."

The commercial conclusion is direct: a new entrant should not assume that a legacy formulation is blocked by active product patents, but it also should not assume that no enforceable rights exist around packaging, manufacturing, combination products or delivery devices. A current patent search is necessary before filing claims or launching a product-specific development program.

When does Cystografin Dilute lose exclusivity?

Cystografin Dilute is a legacy product, so the principal exclusivity questions are regulatory rather than molecule-patent driven.

Exclusivity type	Relevance to Cystografin Dilute
New chemical entity exclusivity	Not expected to be commercially relevant
Five-year NCE exclusivity	Not applicable to a legacy diatrizoate product
Three-year clinical-investigation exclusivity	Possible only after qualifying new clinical investigations
Orphan-drug exclusivity	Not expected for the established cystography indication
Pediatric exclusivity	Only relevant if separately awarded
Listed patent exclusivity	Must be checked against the current FDA Orange Book
Regulatory exclusivity for a new formulation	Possible if statutory requirements are met

For a generic or follow-on product, the critical questions are whether Cystografin Dilute is listed in the FDA Orange Book, whether it has listed patents, whether any exclusivity remains active and whether FDA has established product-specific bioequivalence or pharmaceutical-equivalence requirements.

The Orange Book is the controlling source for listed patents and therapeutic-equivalence information, not commercial product websites or historical package inserts (FDA, Orange Book).

What is the Orange Book status of Cystografin Dilute?

The Orange Book analysis should focus on the specific reference-listed drug, dosage form, strength and applicant. The relevant review points are:

1. Whether Cystografin Dilute has an active reference-listed drug entry.
2. Whether the entry is associated with an NDA or an older product record.
3. Whether any patents are listed under the drug product.
4. Whether the listing has a therapeutic-equivalence code.
5. Whether a generic applicant could use an ANDA pathway.
6. Whether FDA has issued product-specific guidance for the drug.

An applicant should not treat the existence of a marketed product as proof that an ANDA pathway is available. Older contrast products can have complex regulatory histories, legacy NDA records or formulation differences that affect the filing route.

A potential applicant may evaluate:

• An ANDA based on pharmaceutical equivalence and bioequivalence.
• A 505(b)(2) application if the proposed product differs materially in formulation, concentration, presentation or clinical use.
• A drug-device combination pathway if the commercial product includes a proprietary catheter or administration system.

Are there Paragraph IV challenges or generic litigation involving Cystografin Dilute?

Paragraph IV risk depends on active Orange Book-listed patents. A Paragraph IV certification would be relevant only if the reference product has listed patents with remaining enforceable terms. For a mature diatrizoate meglumine product, the higher probability is that competition would arise through regulatory substitution, contract bidding or supply agreements rather than a high-value patent dispute.

The litigation review should cover:

• Abbreviated new drug applications referencing Cystografin Dilute.
• Paragraph IV notices.
• Hatch-Waxman litigation in federal district courts.
• Patent Trial and Appeal Board proceedings.
• Product liability cases involving intravesical contrast administration.
• Contract disputes involving hospital supply or authorized distribution.
• FDA enforcement actions involving sterility or manufacturing quality.

No commercial launch plan should rely on the absence of a publicly visible lawsuit. A patent owner can assert rights after a notice, and a product may have non-patent regulatory barriers that do not appear in patent litigation databases.

What manufacturing and intellectual-property barriers exist?

The most important barrier is sterile manufacturing. Cystografin Dilute appears simple because it is an aqueous solution, but the process requires control of:

• Bioburden before sterilization or aseptic filling.
• Endotoxin.
• Particulate matter.
• Solution clarity.
• Fill-volume accuracy.
• Container closure integrity.
• Active concentration.
• Iodine content.
• pH and osmolality.
• Extractables and leachables.
• Stability under shipping and storage conditions.

The formulation may be manufactured through terminal sterilization if the product and packaging tolerate the process. If not, aseptic processing may be required. The selection affects capital cost, validation burden and the likelihood of supply interruption.

A manufacturer should also qualify multiple suppliers for diatrizoate meglumine, meglumine, water-system components, closures and primary containers. A single-source active ingredient creates a commercial vulnerability even when the formulation itself is off-patent.

What commercial opportunities exist for Cystografin Dilute?

Authorized generic or ANDA supply

The most direct opportunity is a therapeutically equivalent or closely comparable sterile product. Success would depend on FDA pathway, reference-product availability, product-specific requirements and manufacturing economics.

The market is likely smaller than the market for intravenous contrast agents, but competition may also be limited. Hospitals may value dependable supply more than minor formulation differentiation.

Contract manufacturing

A contract manufacturer with sterile liquid capability could offer:

• Finished-dose supply.
• Secondary packaging.
• Hospital-specific labeling.
• Distributor-ready configurations.
• Backup production capacity.
• Regulatory support for a 505(b)(2) or ANDA program.

This model is attractive where the originator or current supplier has intermittent availability or limited manufacturing capacity.

Ready-to-use procedural kits

A kit combining sterile contrast with compatible administration components could reduce preparation time in urology and radiology departments. Potential components include:

• Premeasured contrast.
• Syringe or transfer device.
• Sterile tubing.
• Catheter compatibility documentation.
• Procedure-specific labeling.

The kit could create additional intellectual-property value through the device, packaging configuration or workflow rather than the contrast composition.

Pediatric and low-volume presentations

Pediatric and small-patient procedures may benefit from smaller fill volumes that reduce waste and simplify dose handling. Commercial opportunities include:

• Smaller sterile containers.
• Unit-dose syringes.
• Lower-volume presentations.
• Procedure-specific packaging.
• Barcode and electronic inventory integration.

The product must maintain the same approved clinical use and avoid creating dosing confusion between concentrations.

Supply-chain differentiation

Hospitals often experience more operational risk from shortages than from formulation differences. A supplier can differentiate through:

• Dual-source raw materials.
• Domestic fill-finish capacity.
• Shorter lead times.
• Transparent shortage communication.
• Shelf-life extension supported by stability data.
• Distributor inventory programs.

This is a commercial opportunity even when patent protection is weak.

How does Cystografin Dilute compare with other iodinated contrast products?

Cystografin Dilute should not be positioned as a direct substitute for high-concentration intravenous products. The products differ in route, concentration, osmolality, labeling and clinical use.

Product category	Typical commercial role	Relevance to Cystografin Dilute
Dilute intravesical diatrizoate	Cystography and bladder imaging	Direct comparator
Concentrated diatrizoate products	Gastrointestinal or other radiographic procedures	Limited substitution
Nonionic iodinated contrast	Intravenous CT and angiography	Different route and clinical profile
Low-osmolar contrast media	Modern systemic imaging	Not a direct formulation substitute
Ultrasound contrast agents	Ultrasound enhancement	Different technology and indication
MRI contrast agents	Magnetic resonance imaging	No direct substitution

The primary competitive advantage of Cystografin Dilute is fit-for-purpose use in urinary tract imaging. A new entrant should compete on availability, packaging, procedural efficiency and institutional cost rather than attempting to position the product against modern intravenous nonionic agents.

What regulatory strategy is most practical?

A development program should begin with the current reference product and FDA regulatory record. The preferred route depends on whether the proposed product is pharmaceutically equivalent and whether FDA recognizes the reference product for an abbreviated pathway.

A practical sequence is:

1. Confirm the reference-listed drug and current labeling.
2. Map active ingredients, excipients, concentration and container closure.
3. Confirm Orange Book patents and exclusivity.
4. Assess ANDA eligibility.
5. Identify any product-specific FDA guidance.
6. Develop comparative chemistry, stability and sterility data.
7. Establish container closure and extractables/leachables packages.
8. Validate the sterile manufacturing process.
9. Prepare a 505(b)(2) strategy if the formulation or presentation departs materially from the reference product.

The applicant should use current FDA guidance on ANDA submissions, pharmaceutical equivalence, bioequivalence, container closure systems and sterile drug manufacturing. Relevant quality expectations also arise under 21 C.F.R. Parts 210 and 211 and USP general chapters addressing sterility, bacterial endotoxins, particulate matter and packaging systems.

What is the patent strength of the Cystografin Dilute opportunity?

The patent strength is likely low for the basic active ingredient and conventional dilute aqueous formulation. It can be moderate for a differentiated commercial system built around:

• A validated low-extractables container.
• A novel sterile prefilled syringe.
• A catheter-compatible delivery assembly.
• A stability-enhancing but minimal excipient system.
• A pediatric unit-dose format.
• A manufacturing process that reduces particles or improves shelf life.
• A combination product with proprietary procedural components.

The strongest filing strategy would avoid broad claims covering diatrizoate meglumine in water. Such claims would face substantial prior-art exposure. Narrow claims tied to measured stability, packaging performance, administration systems or manufacturing controls have a more credible commercial purpose.

Key Takeaways

• Cystografin Dilute is a legacy sterile aqueous diatrizoate meglumine product used for intravesical urinary tract imaging.
• Its excipient strategy should remain minimal, preservative-free and focused on stability, sterility and container compatibility.
• The strongest opportunities are authorized-generic supply, contract manufacturing, ready-to-use procedural kits, pediatric packaging and supply-chain reliability.
• Basic composition-of-matter and conventional formulation patent protection is unlikely to be the main barrier.
• Packaging, delivery devices, manufacturing processes and combination products may support new patent value.
• Orange Book status, listed patents, reference-product eligibility and FDA pathway must be confirmed before committing to an ANDA or 505(b)(2) program.
• Commercial differentiation is more likely to come from availability, hospital contracting and procedural efficiency than from a new excipient.

FAQs

Can a new manufacturer use a different excipient system for Cystografin Dilute?

Yes, but the manufacturer must demonstrate pharmaceutical quality, stability, sterility, compatibility and equivalent performance. A materially different excipient system may support a 505(b)(2) application rather than a straightforward ANDA.

Is a preservative-free Cystografin Dilute presentation commercially attractive?

Yes. A single-dose, preservative-free presentation can reduce preservative-related concerns, simplify urinary tract administration and support hospital procedure standardization.

Could a prefilled syringe create new patent protection?

Potentially. Patent value would depend on the specific syringe, closure, compatibility, fill configuration, administration method and evidence of technical benefit. The diatrizoate solution alone would provide a weaker patent foundation.

Is Cystografin Dilute interchangeable with modern low-osmolar intravenous contrast?

No. The products differ in route, concentration, labeling and clinical use. Cystografin Dilute is designed for intravesical urinary tract imaging, not routine intravenous CT or angiography.

What is the most defensible commercial entry strategy?

The strongest strategy is a regulatory-compliant sterile equivalent supported by reliable supply, competitive hospital pricing and improved unit-dose or procedural packaging. A complex new excipient platform would add development risk without a clear commercial advantage.

References

1. U.S. Food and Drug Administration. (n.d.). Cystografin Dilute prescribing information. FDA-approved labeling.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: Generic drug products. FDA guidance and regulatory resources.

4. U.S. Food and Drug Administration. (n.d.). Sterile drug products produced by aseptic processing: Current good manufacturing practice. FDA guidance for industry.

5. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. Parts 210 and 211: Current good manufacturing practice for finished pharmaceuticals.

6. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. General chapters addressing sterility, bacterial endotoxins, particulate matter and packaging systems.